Click Here to return To Results

 

Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019 See this aricle in Pubmed Article Abstract Compared with placebo, inebilizumab reduced the risk of an NMOSD attack. Inebilizumab has potential application as an evidence-based treatment for patients with NMOSD.

Related Tags

(click to filter results - removes previous filter) blindness efficacy inebilizumab monoclonal antibodies neuromyelitis optica (Devic's disease) neuromyelitis optica spectrum disorder safety treatment of neurologic disorder

Click Here to return To Results